Latest Biotech News

Aktis Oncology filed for an initial public offering to raise capital for clinical development of its miniprotein radiopharmaceuticals, following partnerships and investments from Eli Lilly,...

Multiple late‑stage readouts in 2025 strengthened the commercial and clinical case for minimal residual disease (MRD) testing; the Phase III IMvigor011 trial used Natera’s tumor‑informed Signatera...

The FDA approved an oral formulation of Novo Nordisk’s GLP‑1 obesity drug, and the company is preparing a broad commercial launch. The approval makes Wegovy the first oral GLP‑1 cleared...

Boehringer Ingelheim and Boston startup Rectify Pharmaceuticals signed a research and licensing agreement to advance oral therapies for chronic kidney disease, a partnership that could deliver up...

AstraZeneca paid $100 million upfront to outlicense ex‑China rights for Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor JAB‑23E73 in a deal that can total roughly $1.9 billion. AstraZeneca...

Windward Bio acquired ex‑China rights to Qyuns Therapeutics’ clinical‑stage bispecific WIN027 (QX027N), a TSLP/IL‑13 dual antibody, in a deal that could reach $700 million. Windward said the...

Gilead Sciences exercised its option to license two helicase‑primase inhibitors for recurrent genital herpes from Assembly Biosciences, paying $35 million upfront. The compounds, ABI‑1179 and...

Aktis Oncology filed for an initial public offering to finance clinical development of miniprotein radioconjugates, including a Nectin‑4‑targeting candidate in U.S. phase 1b testing. The company,...

Clinical trial readouts and commercial consolidation in 2025 strengthened the minimal residual disease (MRD) testing market, with the Phase III IMvigor011 trial standing out as randomized data...

Pfizer informed investigators and regulators that a participant in a Hympavzi hemophilia trial died after a cerebellar infarction followed by a cerebral hemorrhage. The company disclosed the...

Samsung Biologics America agreed to acquire Human Genome Sciences’ Rockville manufacturing facility from GSK for $280 million, a purchase that preserves more than 500 jobs and adds cGMP capacity...

Chinese molecular diagnostics and precision medicine firm GenePlus Technology filed for an IPO on the Hong Kong Stock Exchange, listing precision diagnostics, clinical R&D enablement and AI‑driven...

The FDA approved an oral formulation of Novo Nordisk’s weight‑loss drug Wegovy, marking the first pill version of a GLP‑1 therapy cleared for obesity. Regulators cleared the pill for weight...

The FDA granted marketing clearance for Cytokinetics’ aficamten (Myqorzo) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM), making a daily oral myosin inhibitor available to...

Samsung Biologics America signed a definitive agreement to acquire Human Genome Sciences’ Rockville, Maryland, manufacturing site from GSK for $280 million, with closing expected by the end of Q1...

Pfizer disclosed that a participant in a clinical trial of its hemophilia drug Hympavzi died after a cerebellar infarction followed by cerebral hemorrhage. The company notified investigators and...

Neurocrine Biosciences reported that valbenazine (Ingrezza) failed to meet its primary endpoint in the Phase 3 KINECT‑DCP trial for dyskinetic cerebral palsy. The company issued an update...

Jacobio Pharmaceuticals out‑licensed its clinical‑stage pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion, with AstraZeneca taking development and commercialization...

Aktis Oncology filed for an initial public offering to fund clinical development of miniprotein radioconjugates, aiming to advance candidates such as Ac‑AKY‑1189 for Nectin‑4‑expressing tumors....

Boehringer Ingelheim agreed to invest $10 billion in U.S. pharmaceutical R&D and manufacturing through 2028 and to join the TrumpRx.gov direct‑purchase platform, under an arrangement that secures...